Mains Practice Questions

Stakeholders Involved

• Affected Children: Primary victims whose fundamental right to life, health, and safety has been directly violated due to consumption of contaminated medicines.
• Families of the Deceased Children: Seek justice, accountability, compensation, and assurance that similar tragedies will not recur.
• Pharmaceutical Manufacturing Company: Responsible for ensuring quality control, ethical production practices, and compliance with drug safety regulations.
• Dr. Ananya Rao (Drug Regulator): Holds statutory and moral responsibility to protect public health, enforce regulations, and uphold medical ethics.
• Drug Regulatory Institutions: Agencies tasked with inspection, monitoring, licensing, and enforcement of pharmaceutical standards.
• Healthcare Professionals: Doctors and pharmacists whose credibility, trust relationship with patients, and ethical duty of care are affected by drug safety failures.
• Government and Political Leadership: Balances public health priorities with economic growth, employment concerns, and international diplomatic considerations.
• Pharmaceutical Workers: Employees whose livelihoods and job security may be impacted by regulatory actions against the company.
• Export Partners and Importing Countries: Stakeholders concerned with regulatory reliability, drug safety, and the global reputation of Indian pharmaceuticals.
• General Public: Depend on affordable yet safe medicines and are affected by erosion of trust in the healthcare and regulatory system.
  
  

Q1.Discuss the ethical dilemma between affordability of medicines, industrial growth, and the principle of ‘non malfiance’ in Bio ethics ethics.

Ethical Dilemmas:

• Affordability of Medicines- Ethics of Access: Affordability of medicines is ethically linked to social justice and equity, as low-cost drugs ensure access to healthcare for the poor and vulnerable.
  • In a country with high out-of-pocket expenditure, affordable medicines promote collective welfare.
  • However, when affordability is achieved by compromising quality and safety, it becomes ethically indefensible, as access to unsafe medicines violates the core purpose of healthcare ethics.
• Industrial Growth-Ethics of Development: Pharmaceutical industrial growth supports employment, exports, and innovation, making it ethically desirable from a developmental perspective.
  • However, growth driven solely by profit risks ethical erosion if regulatory compliance is weakened. Medicines are moral goods, not ordinary commodities, and economic development that tolerates harm undermines long-term trust and sustainability.
• Principle of Non-Maleficence- Non-Negotiable: Non-maleficence, or “do no harm,” is the foundational principle of bioethics. Any preventable harm caused by unsafe medicines is an absolute ethical violation, regardless of economic or accessibility benefits.
  • This principle sets a moral baseline that cannot be traded off for affordability or growth.

The dilemma appears as a trade-off between affordability, growth, and safety, but ethically it is a false choice.

• Non-maleficence must form the ethical floor, while affordability and growth must operate within strict safety boundaries to retain moral legitimacy.

Q2.What options are available to Dr. Ananya Rao in responding to this crisis? Evaluate the ethical merits and limitations of each option.

Options Available to Dr Ananya Rao:

• Option 1: Maintain Status Quo With Advisory and Internal Review
  • Merits:
    • Avoids immediate disruption to medicine supply, employment, and exports.
    • Minimizes political and industrial backlash in the short term.
  • Demerits
    • Violates non-maleficence and accountability by tolerating preventable harm.
    • Erodes public trust and signals regulatory complacency.
• Option 2: Immediate Suspension of License and Criminal Action
  • Merits
    • Strongly upholds non-maleficence, justice, and rule of law.
    • Acts as a deterrent against future negligence and restores public confidence.
  • Demerits
    • May cause short-term drug shortages and job losses.
    • Risks political pressure and investor anxiety.
• Option 3: Independent Investigation With Time-Bound Regulatory Action
  • Merits
    • Ensures procedural fairness, transparency, and evidence-based decision-making.
    • Balances accountability with due process.
  • Demerits
    • Delayed outcomes may be perceived as regulatory softness.
    • Interim risks persist if immediate safeguards are not imposed.
• Option 4: Product Recall, Compensation, and Corrective Compliance Measures
  • Merits
    • Provides immediate relief to victims and prevents further harm.
    • Demonstrates ethical responsiveness and empathy.
  • Demerits
    • Without penal action, it weakens deterrence and moral accountability.
    • Risks reducing the issue to a financial settlement.
• Option 5: Systemic Reforms Without Retrospective Punishment
  • Merits
    • Strengthens long-term regulatory capacity and prevention mechanisms.
    • Improves institutional resilience and quality assurance.
  • Demerits
    • Denies justice to victims and normalizes past ethical failures.
    • Undermines credibility of ethical governance.

Option 3 is the best core choice as it balances justice, due process, and transparency, ensuring evidence-based action while protecting institutional credibility and avoiding politicisation. It reflects administrative prudence and reassures both citizens and global partners that drug safety is non-negotiable. However, Option 3 alone is insufficient. It must be reinforced by:

• Selective elements of Option 2: Interim suspension of the concerned batch/line and criminal prosecution where wilful negligence is proven, to uphold non-maleficence and deterrence.
• Humanitarian elements of Option 4: Immediate product recall, compensation, and empathetic victim-centric communication, reflecting compassion and restorative justice.
  • This combined approach ensures moral completeness, accountability, and public trust.

Q3. What course of action should Dr. Rao adopt to uphold medical ethics, accountability, and public interest while ensuring long-term credibility of the health system? Justify your answer.

Course of Action and Justification

• Short term:
  • Interim Suspension of Manufacturing License of the concerned pharmaceutical unit with immediate effect to prevent further harm.
    • This prioritizes the principle of non-maleficence by preventing further harm and demonstrates that patient safety overrides economic or political considerations.
  • Order Nationwide Recall of the contaminated cough syrup batch and issue urgent public health advisories.
    • A recall minimizes risk to the public and reflects the precautionary principle, reinforcing the regulator’s ethical duty to protect life.
  • Independent, Time-Bound Investigation by constituting an independent technical and judicial inquiry with clear timelines.
    • It ensures transparency in findings to uphold justice, fairness, and institutional credibility.
  • Initiate Criminal Investigation against responsible company officials for negligence and violation of drug safety norms where wilful negligence is proven.
    • Legal accountability upholds justice and deterrence, affirming that loss of life due to negligence is a serious ethical and legal violation.
  • Ensure Time-Bound Compensation to affected families through appropriate legal and administrative mechanisms.
    • Compensation addresses restorative justice, acknowledges state responsibility, and provides moral and material relief to victims.
  • Maintain Full Transparency by publicly disclosing investigation findings to restore public trust.
    • Transparency builds public trust, counters misinformation, and reflects ethical leadership based on honesty and accountability.
• Long Term:
  • Strengthen Regulatory Oversight through independent audits, frequent inspections, and strict enforcement of quality standards.
    • Strong oversight prevents recurrence of harm and aligns with the ethical obligation of prevention in public health.
  • Improve Quality-Control Systems by mandating better testing, traceability of raw materials, and compliance with good manufacturing practices to prevent recurrence.
    • Systemic reforms ensure long-term credibility of the health system and ethically balance affordability with uncompromised safety.

Conclusion:

This case underscores that in medical ethics, human life and safety are non-negotiable values. Affordability and industrial growth are meaningful only when anchored in the principle of non-maleficence. By acting with firmness, transparency, and accountability, Dr. Rao can restore public trust, ensure justice for victims, and reinforce the credibility of the health system. Ethical governance in healthcare ultimately demands moral courage where protecting life takes precedence over economic convenience or political pressure.